| | AD (n= 54) | MCI (n= 75) | Controls (n= 25) |
|---|
Age, years | 75 (6.2) | 68 (9.3) | 74 (6.7) |
Gender, male/female | 17/37 | 29/46 | 6/19 |
MMSE, score | 19 (4.9)a | 27 (1.6) | 29 (1.4) |
Plasma T-tau, pg/mL | 8.80 (10.1)b,c | 4.68 (4.25) | 4.43 (2.83) |
CSF T-tau, pg/mL | 828 (375)a | 550 (421) | 507 (254) |
CSF P-tau, pg/mL | 123 (49.2)a | 78.1 (28.8) | 73.4 (20.5) |
CSF Aβ42, pg/mL | 380 (87.6)a | 478 (204) | 584 (215) |
- Quantitative data are presented as mean (standard deviation). Statistical differences were determined by using nonparametric tests. Cerebrospinal fluid (CSF) biomarker concentrations are INNOTEST ELISA-normalized Luminex AlzBio3 (Innogenetics, Gent, Belgium) values. aCompared with patients with mild cognitive impairment (MCI) or controls, P <0.001. bCompared with patients with MCI, P = 0.001. cCompared with controls, P = 0.02. AD, Alzheimer's disease; MMSE, mini-mental state examination.
